+ Follow TEVA PHARMACEUTICALS AND IVAS PHARMACEUTICAL Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 184159
[Title] => US court upholds patent for drug
[Summary] => A US federal court recently upheld the patent for Fosomax, a blockbuster osteoporosis drug produced by Merck, a US pharmaceuticals group which was being challenged by two generic drug makers to enable them to make cheaper versions of the drug.
A Financial Times report from New York said a district court in Delaware ruled against Teva Pharmaceuticals and Ivas Pharmaceutical, two Israeli companies which were attempting to launch inexpensive versions of Fosomax. Mercks patent on the drug, which generated $455 million in sales last quarter, is valid until August 2007.
[DatePublished] => 2002-11-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Business
[SectionUrl] => business
[URL] =>
)
)
)
TEVA PHARMACEUTICALS AND IVAS PHARMACEUTICAL
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 184159
[Title] => US court upholds patent for drug
[Summary] => A US federal court recently upheld the patent for Fosomax, a blockbuster osteoporosis drug produced by Merck, a US pharmaceuticals group which was being challenged by two generic drug makers to enable them to make cheaper versions of the drug.
A Financial Times report from New York said a district court in Delaware ruled against Teva Pharmaceuticals and Ivas Pharmaceutical, two Israeli companies which were attempting to launch inexpensive versions of Fosomax. Mercks patent on the drug, which generated $455 million in sales last quarter, is valid until August 2007.
[DatePublished] => 2002-11-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Business
[SectionUrl] => business
[URL] =>
)
)
)
abtest
November 16, 2002 - 12:00am